The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...
Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...
After hours: March 17 at 4:20:00 PM EDT Loading Chart for NBIX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback